Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and children. DM can be life-threatening (interstitial lung disease, infectious complications) and responsible of significant functional disability (muscle weakness). Age of onset appear to be an independent prognostic factor. Juvenile-onset DM is characterized by a higher frequency of calcinosis, skin ulceration and digestive vasculitis. In adults, interstitial lung disease and cancer are more frequent with higher mortality. Data concerning the comparison of the initial severity between juvenile and adult-onset DM are limited.

The main objective is to compare global severity between juvenile DM and adult-onset DM at initial diagnosis.

Secondary objectives are:

* to compare organ-specific severity between juvenile DM and adult-onset DM at diagnosis.
* to compare damage during follow-up and at last follow-up between juvenile DM and adult-onset DM.
* to compare activity at the last follow-up between juvenile DM and adult-onset DM.
* to compare iatrogenic complications between juvenile DM and adult-onset DM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Juvenile Autoimmune Necrotizing Myopathies

NCT04295785

Immune-Mediated Necrotizing Myopathy

UNKNOWN

Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis

NCT00059748

Autoinflammatory Disease Juvenile Dermatomyositis

RECRUITING

Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis

NCT02556866

Cryoglobulinemia Systemic Vasculitis

TERMINATED PHASE2

Clinical Analysis of Juvenile Dermatomyositis Patients

NCT05509140

Juvenile Dermatomyositis

COMPLETED

Evaluation of Peripheral Neutrophils in Antisynthetase Syndrome

NCT05691725

Antisynthetase Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatomyositis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Juvenile dermatomyositis

Dermatomyositis before 18 years-old

evaluation of clinical severity

Intervention Type OTHER

evaluation of clinical severity

Adult-onset dermatomyositis

Dermatomyositis from 18 years-old

evaluation of clinical severity

Intervention Type OTHER

evaluation of clinical severity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

evaluation of clinical severity

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with dermatomyositis according to 2017 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) classification